PR
GLUE icon

PSP Research’s Monte Rosa Therapeutics GLUE Stock Holding History

PSP Research’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$557K Sell
23,000
-5,000
-18% -$94.5K 0.3% 11
2026
Q1 		$461K Buy
+28,000
New +$535K 0.33% 33

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PSP Research's GLUE Position: Q2 2026 in Review

PSP Research reduced its Monte Rosa Therapeutics (GLUE) stake by 18% in Q2 2026, selling an estimated $94.5K and leaving 23,000 shares worth $557K. The position accounts for 0.3% of the portfolio, ranked #11.

PSP Research first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • PSP Research held 23,000 shares of Monte Rosa Therapeutics worth $557K as of Q2 2026.
  • PSP Research sold 5,000 Monte Rosa Therapeutics shares in Q2 2026, an estimated $94.5K.
  • Monte Rosa Therapeutics made up 0.3% of PSP Research's portfolio in Q2 2026, its #11 holding.
  • PSP Research first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.